XASE · Healthcare · Biotechnology
Armata Pharmaceuticals Inc is a late clinical-stage biotechnology company focused on the development of high-purity and potent, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using proprietary bacteriophage-based technology. It has completed three Phase 2 clinical trials to date. The Company operates and manages its business as one reportable operating segment, which is the business of developing pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat acute and chronic bacterial infections using its proprietary bacteriophage-based technology.
Armata’s main catalyst is **AP-SA02** advancing toward a planned Phase 3 superiority study, a meaningful de-risking step for the late-stage phage platform. Q2 showed a narrow EPS beat at **$(0.27)** versus $(0.45) and $3M revenue, but losses remain severe and execution risk high.
AI-generated summary — powered by BigEarnings.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-12 | Q2 2026 | -0.45 | -0.27 | +40.00% | $2.5M | ✅ Beat | +1.16% | +17.63% | — |
| 2026-05-13 | Q1 2026 | -0.39 | -3.16 | -710.26% | $789,000 | ❌ Miss | +0.40% | -7.94% | -14.06% |
| 2026-03-25 |
| Q4 2025 |
| -0.19 |
| -3.43 |
| -1705.26% |
| $1.1M |
| ❌ Miss |
| -2.44% |
| +22.65% |
| +50.06% |
| 2025-11-12 | Q3 2025 | -0.42 | -0.74 | -76.19% | $1.2M | ❌ Miss | — | — | — |
| 2025-08-12 | Q2 2025 | -0.39 | -0.45 | -15.38% | $2.2M | ❌ Miss | -4.07% | +3.25% | +20.33% |
| 2025-03-20 | Q4 2024 | -0.35 | -0.23 | +34.29% | $1.2M | ✅ Beat | -10.95% | -17.91% | -38.31% |
| 2024-11-13 | Q3 2024 | -0.28 | -0.15 | +46.43% | $3.0M | ✅ Beat | -1.47% | -23.16% | -19.42% |
| 2024-08-13 | Q2 2024 | -0.44 | -0.25 | +43.18% | $0 | ✅ Beat | -10.70% | -12.55% | -18.82% |
Showing last 8 quarters.